Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Immuneering CorporationNASDAQ: IMRX
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $1.87M rose 327.7% year over year, ahead of the +95.0% change in trailing-twelve-month other income / expenses. Sequentially, it fell 13.7% from the prior quarter. Over 3 fiscal years it compounded at +39.6% a year.
Context
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +327.7% holds above the trailing-twelve-month pace of +95.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 3.35M USD
- Year-over-year change
- +10.4%
- 4-year CAGR
- +197.4%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.35M | +10.4% |
| FY2024 | 2024-12-31 | 3.03M | -38.6% |
| FY2023 | 2023-12-31 | 4.94M | +301.4% |
| FY2022 | 2022-12-31 | 1.23M | +2773.5% |
| FY2021 | 2021-12-31 | 42.83K | — |
Other Income / Expenses vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's LTM Mar 2026 other income / expenses of $4.79M is the 9th highest of the 11 companies compared; the peer median is $6.55M.
- Its year-over-year change of +95.0% is the highest of 11, against a peer median of -31.4%.
- Over three fiscal years its annual growth of +39.6% compares with a peer median of +11.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.3M | -51.1% | -2.8% | 808.4% | |
| LTM Mar 2026 | $13.26M | -32.7% | +71.0% | 231.0% | |
| LTM Mar 2026 | $10.54M | -22.0% | — | 23.2% | |
| LTM Mar 2026 | $7.16M | +37.9% | +80.4% | 10.1% | |
| LTM Mar 2026 | $7.03M | -30.0% | +11.2% | — | |
ZURAZura Bio Limited | LTM Mar 2026 | $6.06M | +52.8% | — | — |
| LTM Mar 2026 | $5.52M | -41.1% | +30.8% | 39.8% | |
| LTM Mar 2026 | $5.44M | -67.9% | -1.8% | 19.3% | |
| LTM Mar 2026 | $4.79M | +95.0% | +39.6% | — | |
| LTM Mar 2026 | $2.85M | -27.9% | +11.8% | 1268.0% | |
| LTM Mar 2026 | -$1.51M | -146.9% | +2.8% | 2.2% | |
| Peer median (excluding IMRX) | $6.55M | -31.4% | +11.5% | 31.5% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.08M | 316.95K | 0 | 0 | 0 |
| Cost of Revenue | 1.15M | 158.12K | 0 | 0 | 698.89K |
| Gross Profit | 926.89K | 158.83K | 0 | 0 | (698.89K) |
| Gross Margin | 44.6% | 50.1% | — | — | — |
| Research & Development | 26.54M | 36.27M | 41.62M | 47.96M | 42.05M |
| Selling, General & Admin | 8.27M | 15.61M | 16.76M | 16.08M | 17.3M |
| Operating Expenses | 34.81M | 51.9M | 58.41M | 64.07M | 58.68M |
| Depreciation & Amortization | 159.07K | 277.25K | 352.08K | 385.07K | 698.89K |
| EBITDA | (33.68M) | (51.47M) | (58.06M) | (63.69M) | (55.33M) |
| EBITDA Margin | -1619.5% | -16238.4% | — | — | — |
| Operating Income | (33.89M) | (51.74M) | (58.41M) | (64.07M) | (59.38M) |
| Operating Margin | -1629.2% | -16325.8% | — | — | — |
| Interest Income | 169.9K | 1.01M | 3.61M | 2.59M | 3.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 42.83K | 1.23M | 4.94M | 3.03M | 3.35M |
| Income Before Tax | (33.84M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Pre-Tax Margin | -1627.1% | -15937.4% | — | — | — |
| Income Tax Expense | (307.49K) | 0 | 0 | 0 | 0 |
| Net Income | (33.54M) | (50.51M) | (53.47M) | (61.04M) | (56.02M) |
| Net Margin | -1612.3% | -15937.3% | — | — | — |
| EPS (Basic) | (1.27) | (1.87) | (1.88) | (2.04) | (1.27) |
| EPS (Diluted) | (1.27) | (1.87) | (1.88) | (2.04) | (1.27) |
| Weighted Avg Shares | 26.32M | 26.39M | 28.42M | 29.98M | 44.01M |
| Weighted Avg Shares (Diluted) | 26.32M | 26.39M | 28.42M | 29.98M | 44.01M |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.